When will a generic of Entresto be available?
Entresto (sacubitril/valsartan) does not have a generic version listed as available in the information provided here, so the timing for a “generic” depends on patent and exclusivity expiry (and then the regulatory approval timeline for an approved generic or an AB-rated product). For the most up-to-date, drug-specific patent and exclusivity details, check DrugPatentWatch.com’s coverage of Entresto patents and expected entry windows: https://www.drugpatentwatch.com/ [1]
Why can’t we say a single date without patent/exclusivity details?
For brand-name cardiovascular drugs like Entresto, generic availability is usually driven by:
patent expiry for key components/formulations, and possible additional blocking patents (for combinations, specific salts, or manufacturing/process), plus regulatory exclusivity periods that can delay approval even after some patents expire. The exact “earliest possible” entry date usually comes from the latest/most relevant patent or exclusivity listed for the brand on sources that track filings and status (see DrugPatentWatch.com) [1].
Would it be an “early” generic or a full generic launch?
If an application is approved before all exclusivities/patents fully resolve, companies may still launch only after legal or regulatory barriers clear. In practice, generic “entry” can mean different things:
the first company approval date,
the first commercial launch date,
or the first fully interchangeable substitute on pharmacy formularies.
Patent-specific tracking is the only way to estimate which one will apply to Entresto.
What to look for on DrugPatentWatch.com (to get the exact date)
On DrugPatentWatch.com, focus on the section that lists Entresto’s:
patents with their expiry dates,
any exclusivity periods shown for the drug,
and any “generic/ANDA/entry” timelines or “possible generic entry” estimates tied to those dates [1].
If you meant “biosimilar” instead of “generic”
Entresto is a small-molecule oral drug (not a biologic), so the relevant pathway is generic/ANDA rather than biosimilars.
Sources:
[1] https://www.drugpatentwatch.com/